Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
EDIT Editas Medicine	$2.73 -3.9%	$2.09	$0.91 ▼ $5.85	$237.74M	2.15	2.64 million shs	1.83 million shs
FNCH Finch Therapeutics Group	$12.50 -2.0%	$13.24	$1.27 ▼ $15.85	$20.08M	1.21	2,104 shs	329 shs
IMUX Immunic	$0.93 +3.8%	$0.82	$0.56 ▼ $2.11	$85.83M	1.49	983,881 shs	1.29 million shs
ORMP Oramed Pharmaceuticals	$2.12 +0.5%	$2.18	$1.82 ▼ $3.09	$86.19M	1.59	140,735 shs	38,553 shs

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
EDIT Editas Medicine	+3.27%	-7.79%	+31.48%	+121.01%	-52.35%
FNCH Finch Therapeutics Group	-1.96%	-3.85%	-8.09%	-3.85%	+691.14%
IMUX Immunic	+7.53%	+11.17%	+9.18%	-8.59%	-39.47%
ORMP Oramed Pharmaceuticals	+0.96%	-2.76%	-2.31%	-1.86%	-17.58%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
EDIT Editas Medicine	4.111 of 5 stars	3.2	2.0	4.3	2.8	2.5	0.6
FNCH Finch Therapeutics Group	0.7895 of 5 stars	0.0	5.0	0.0	0.0	1.7	0.6
IMUX Immunic	2.5034 of 5 stars	3.6	1.0	0.0	2.5	2.5	0.6
ORMP Oramed Pharmaceuticals	1.2139 of 5 stars	0.0	4.0	0.0	3.3	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
EDIT Editas Medicine	2.31	Hold	$4.70	72.16% Upside
FNCH Finch Therapeutics Group	0.00	N/A	N/A	N/A
IMUX Immunic	3.29	Buy	$7.50	706.45% Upside
ORMP Oramed Pharmaceuticals	2.00	Hold	N/A	N/A

Current Analyst Ratings Breakdown

Latest FNCH, ORMP, EDIT, and IMUX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/25/2025	IMUX Immunic	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
6/5/2025	IMUX Immunic	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
5/29/2025	IMUX Immunic	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$17.00 ➝ $10.00
5/23/2025	IMUX Immunic	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.00 ➝ $5.00
5/16/2025	IMUX Immunic	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
5/13/2025	EDIT Editas Medicine	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$8.00 ➝ $4.00
5/1/2025	IMUX Immunic	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00
4/30/2025	IMUX Immunic	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$17.00 ➝ $17.00
4/29/2025	EDIT Editas Medicine	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
4/28/2025	EDIT Editas Medicine	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$3.00
4/28/2025	EDIT Editas Medicine	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$3.00

(Data available from 7/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
EDIT Editas Medicine	$32.31M	7.07	N/A	N/A	$1.63 per share	1.67
FNCH Finch Therapeutics Group	N/A	N/A	N/A	N/A	$14.25 per share	N/A
IMUX Immunic	N/A	N/A	N/A	N/A	$0.20 per share	N/A
ORMP Oramed Pharmaceuticals	$1.34M	64.63	N/A	N/A	$3.61 per share	0.59

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
EDIT Editas Medicine	-$237.09M	-$3.04	N/A	N/A	N/A	-701.06%	-139.24%	-63.87%	8/6/2025 (Estimated)
FNCH Finch Therapeutics Group	-$74.75M	-$8.82	N/A	∞	N/A	N/A	-69.14%	-26.92%	N/A
IMUX Immunic	-$100.51M	-$1.23	N/A	N/A	N/A	N/A	-326.95%	-181.34%	8/6/2025 (Estimated)
ORMP Oramed Pharmaceuticals	-$19.06M	-$0.44	N/A	N/A	N/A	N/A	-11.34%	-10.73%	8/13/2025 (Estimated)

Latest FNCH, ORMP, EDIT, and IMUX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q1 2025	IMUX Immunic	-$0.19	N/A	N/A	N/A	N/A	N/A
8/13/2025	N/A	ORMP Oramed Pharmaceuticals	-$0.01	N/A	N/A	N/A	N/A	N/A
8/6/2025	Q2 2025	EDIT Editas Medicine	-$0.40	N/A	N/A	N/A	$1.81 million	N/A
5/15/2025	Q1 2025	IMUX Immunic	-$0.25	-$0.25	N/A	-$0.25	N/A	N/A
5/15/2025	Q1 2025	ORMP Oramed Pharmaceuticals	-$0.03	-$0.19	-$0.16	-$0.19	N/A	$2.00 million
5/12/2025	Q1 2025	EDIT Editas Medicine	-$0.51	-$0.43	+$0.08	-$0.92	$0.79 million	$4.66 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
EDIT Editas Medicine	N/A	N/A	N/A	N/A	N/A
FNCH Finch Therapeutics Group	N/A	N/A	N/A	N/A	N/A
IMUX Immunic	N/A	N/A	N/A	N/A	N/A
ORMP Oramed Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
EDIT Editas Medicine	N/A	3.08	3.08
FNCH Finch Therapeutics Group	N/A	3.87	3.87
IMUX Immunic	N/A	0.74	0.74
ORMP Oramed Pharmaceuticals	N/A	23.94	23.94

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
EDIT Editas Medicine	71.90%
FNCH Finch Therapeutics Group	21.77%
IMUX Immunic	51.82%
ORMP Oramed Pharmaceuticals	12.73%

Insider Ownership

Company	Insider Ownership
EDIT Editas Medicine	2.10%
FNCH Finch Therapeutics Group	44.90%
IMUX Immunic	4.60%
ORMP Oramed Pharmaceuticals	13.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
EDIT Editas Medicine	230	83.71 million	81.96 million	Optionable
FNCH Finch Therapeutics Group	190	1.61 million	885,000	No Data
IMUX Immunic	70	95.82 million	91.41 million	Optionable
ORMP Oramed Pharmaceuticals	10	40.85 million	35.25 million	Optionable

FNCH, ORMP, EDIT, and IMUX Headlines

Recent News About These Companies

ORMP - Oramed Pharmaceuticals Inc Trailing Returns - Morningstar

July 2, 2025 | morningstar.comM

Oramed Pharmaceuticals Inc. (ORMP) - Yahoo Finance

July 2, 2025 | ca.finance.yahoo.com

ORMP - Oramed Pharmaceuticals Inc Executives - Morningstar

June 27, 2025 | morningstar.comM

We're Not Very Worried About Oramed Pharmaceuticals' (NASDAQ:ORMP) Cash Burn Rate

June 27, 2025 | finance.yahoo.com

Oramed Pharmaceuticals (NASDAQ:ORMP) Share Price Passes Above Fifty Day Moving Average - Should You Sell?

June 24, 2025 | marketbeat.com

Oramed Pharm Extends Stock Buyback Program

May 21, 2025 | tipranks.com

The past three years for Oramed Pharmaceuticals (NASDAQ:ORMP) investors has not been profitable

May 17, 2025 | finance.yahoo.com

Oramed Pharmaceuticals Inc.: Oramed Pharmaceuticals Announces $36.9 Million Investment and Strategic Collaboration with Alpha Tau Medical

April 28, 2025 | finanznachrichten.de

Oramed Pharmaceuticals Announces $36.9 Million Investment and Strategic Collaboration with Alpha Tau Medical

April 28, 2025 | prnewswire.com

Alpha Tau Announces Closing of $36.9 Million Registered Direct Offering and Strategic Marketing Alliance with Oramed Pharmaceuticals

April 28, 2025 | globenewswire.com

ORMP: Upcoming Expected Milestones Include OraTech Spin-Off & IPO, Launch of Phase 3 Trial

April 3, 2025 | finance.yahoo.com

Oramed Pharmaceuticals And 2 Other Penny Stocks With Promising Potential

March 15, 2025 | finance.yahoo.com

Oramed Pharmaceuticals Issues Letter to Shareholders

March 4, 2025 | prnewswire.com

OraMed Enters Global Licensing Deal for Lidocaine Product

March 1, 2025 | investing.com

Congressional Trading Report: Rep. Brad Knott Sold Over $15K In Oramed Pharmaceuticals Stock

February 27, 2025 | benzinga.com

Oramed Pharmaceuticals to Spin Off Its Protein Oral Delivery Technology

February 11, 2025 | contractpharma.comC

OraTech to pioneer oral insulin with $75 million investment

February 11, 2025 | msn.com

Oramed enters JV for insulin development and commercialization

February 11, 2025 | markets.businessinsider.com

Oramed Announces Transformative Joint Venture to Accelerate Development and Commercialization of Oral Insulin

February 11, 2025 | prnewswire.com

Scilex announces early installment payment on senior secured promissory note

December 16, 2024 | markets.businessinsider.com

ORMP: Preparations for New Phase 3 Trial Advance, While ORMP Leverages Balance Sheet Through Recent Agreements

December 2, 2024 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Why BigBear.ai Could Rally 100% and Catch Palantir Soon
By Gabriel Osorio-Mazilli | June 30, 2025
View Why BigBear.ai Could Rally 100% and Catch Palantir Soon
3 Defense Leaders Set to Gain From Rising Military Spend
By Chris Markoch | July 5, 2025
View 3 Defense Leaders Set to Gain From Rising Military Spend
IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
EV Tax Credits Are Ending—Here’s Why These 2 Stocks Could Soar
By Leo Miller | July 8, 2025
View EV Tax Credits Are Ending—Here’s Why These 2 Stocks Could Soar
Capitalize on Volatility: 3 Finance Stocks Thriving in 2025
By Chris Markoch | July 2, 2025
View Capitalize on Volatility: 3 Finance Stocks Thriving in 2025

FNCH, ORMP, EDIT, and IMUX Company Descriptions

Editas Medicine NASDAQ:EDIT

$2.73 -0.11 (-3.87%)

Closing price 04:00 PM Eastern

Extended Trading

$2.72 -0.01 (-0.51%)

As of 07:58 PM Eastern

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

Finch Therapeutics Group NASDAQ:FNCH

$12.50 -0.25 (-1.96%)

As of 02:15 PM Eastern

Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in humans, including ulcerative colitis; FIN-525 for the treatment of Crohn's disease; and other microbiome product candidates. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; and license agreements with Skysong Innovations LLC, OpenBiome, Arizona State University, and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Boston, Massachusetts.

Immunic NASDAQ:IMUX

$0.93 +0.03 (+3.82%)

Closing price 04:00 PM Eastern

Extended Trading

$0.94 +0.01 (+1.61%)

As of 07:55 PM Eastern

Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company is also developing IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases. Immunic, Inc. was founded in 2016 and is headquartered in New York, New York.

Oramed Pharmaceuticals NASDAQ:ORMP

$2.12 +0.01 (+0.47%)

Closing price 04:00 PM Eastern

Extended Trading

$2.12 +0.00 (+0.24%)

As of 07:21 PM Eastern

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes. It has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time